The Makerere University-Johns Hopkins University Research Collaboration (MUJHU) began in 1988 by scientists and clinicians from the US and Uganda with a focus on Prevention of Mother-To-Child HIV Transmission (PMTCT) and provision of pediatric HIV services in Uganda, paving way for the large-scale implementation of programs to eliminate vertical HIV transmission and improve prevention and care for HIV-infected and affected women, children and their families.
The collaboration has flourished dramatically into a diverse community of talented clinical investigators, scientific researchers and participants. To date, the site has conducted multiple perinatal HIV prevention trials, including the landmark HIVNET 012 trial whose results were incorporated into WHO and MOH PMTCT guidelines for resource-limited settings around the world. Additionally, pediatric treatment trials include the IMPAACT study P1060, which compared a Nevirapine (NVP)-based versus a Lopinavir/ ritonavir-based antiretroviral regimen in HIV infected children who were exposed and not exposed to NVP at birth.
The results of this study informed the WHO pediatric HIV treatment guidelines for resource limited settings.
Over the last decade, MUJHU has participated as a clinical research site with the NIH Microbicides Trials Network and, in 2016, completed the ASPIRE placebo randomized controlled trial among women using the Dapivirine vaginal ring to reduce HIV sexual acquisition. MUJHU is now participating in the MTN HOPE open label extension study to further assess safety, adherence and acceptability.
For almost 30 years now, MUJHU has contributed directly to local and global policy changes through HIV prevention and care research studies